Condition
Incomplete Reversal of Neuromuscular Block
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
75%
3 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
P 4 (3)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02909439Phase 4CompletedPrimary
Quality of Recovery After Reversal With Neostigmine or Sugammadex.
NCT02568345Phase 4CompletedPrimary
Sugammadex ED90 Dose in the Obese Patients
NCT02137395Phase 4CompletedPrimary
The Effect of Dexamethasone on Sugammadex Reversal
NCT02226809CompletedPrimary
Multi-center Study of Residual Neuromuscular Block Incidence in the Post-anesthesia Care Unit
Showing all 4 trials